US2007148774A1PendingUtilityA1

Methods for producing members of specific binding pairs

63
Assignee: CAMBRIDGE ANTIBODY TECHPriority: Jul 10, 1990Filed: Nov 1, 2006Published: Jun 28, 2007
Est. expiryJul 10, 2010(expired)· nominal 20-yr term from priority
C07K 2319/41C12N 15/73C12N 15/62C07K 2319/735C12N 15/1037Y10S530/867C07K 2319/00C07K 2317/24C07K 2319/02C07K 2317/92C07K 16/462C07K 16/34C07K 19/00C07K 16/18B01J 2219/00718C07K 2317/622C07K 16/44C07K 16/26C07K 16/468C07K 16/005C07K 2317/34C07K 2317/55G01N 33/53C07K 2317/21G01N 33/6857C07K 2317/62C40B 40/02C07K 16/00C07K 16/40
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A member of a specific binding pair (sbp) is identified by expressing DNA encoding a genetically diverse population of such sbp members in recombinant host cells in which the sbp members are displayed in functional form at the surface of a secreted recombinant genetic display package (rgdp) containing DNA encoding the sbp member or a polypeptide component thereof, by virtue of the sbp member or a polypeptide component thereof being expressed as a fusion with a capsid component of the rgdp. The displayed sbps may be selected by affinity with a complementary sbp member, and the DNA recovered from selected rgdps for expression of the selected sbp members. Antibody sbp members may be thus obtained, with the different chains thereof expressed, one fused to the capsid component and the other in free form for association with the fusion partner polypeptide. A phagemid may be used as an expression vector, with said capsid fusion helping to package the phagemid DNA. Using this method libraries of DNA encoding respective chains of such multimeric sbp members may be combined, thereby obtaining a much greater genetic diversity in the sbp members than could easily be obtained by conventional methods.

Claims

exact text as granted — not AI-modified
1 . A phagemid comprising a DNA encoding a single-chain antibody-coliphage pIII fusion protein, wherein the fusion protein contains a contiguous full length coliphage pIII protein.  
     
     
         2 . The phagemid according to  claim 1 , wherein the fusion protein contains a protease-sensitive region between the antibody and the coliphage pIII protein.  
     
     
         3 . The phagemid according to either  claim 1  or  claim 2 , wherein the phagemid comprises the genetic elements and DNA sequences (SEQ ID NOS: 7-17) of FIGS.  1 ( a )-1(c).  
     
     
         4 . A process of producing the phagemid according to  claim 1 , comprising fusing a DNA encoding the single-chain antibody to a DNA encoding the contiguous full length coliphage pIII protein and inserting the resulting DNA into a phagemid vector.  
     
     
         5 . The process according to  claim 4 , further comprising inserting a DNA encoding a protease-sensitive region between the DNA encoding the single-chain antibody and the DNA encoding the coliphage pIII protein.  
     
     
         6 . A method of selecting antibodies from an antibody library, comprising screening said antibody library with an antigen, wherein said antibody library consists of phagemids according to either  claim 1  or  claim 2 .  
     
     
         7 . A method of presenting a peptide or protein at the surface of a phagemid viral particle, comprising producing said phagemid viral particle, wherein said phagemid viral particle comprises a DNA sequence encoding said peptide or protein fused to a DNA sequence encoding a contiguous full length coliphage pIII protein.  
     
     
         8 . A filamentous bacteriophage particle displaying on its surface as a fusion with a gene III coat protein surface component a member of a specific binding pair in functional form comprising a binding domain for a complementary specific binding pair member, the particle containing a phagemid genome which is plasmid nucleic acid containing a single stranded phage replication origin and a nucleotide sequence encoding said fusion, and the particle having a coat partially derived from a helper phage and partly from said fusion.  
     
     
         9 . A particle according to  claim 8  wherein the displayed specific binding pair member comprises a binding domain of an immunoglobulin.  
     
     
         10 . A particle according to  claim 9  wherein the specific binding pair member is a scFv molecule.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.